Author:
Himuro Takanori,Horimoto Yoshiya,Arakawa Atsushi,Matsuoka Joe,Tokuda Emi,Tanabe Masahiko,Saito Mitsue
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–16.
2. Toi M, Nakamura S, Kuroi K, et al. Phase II study of preoperative sequential FEC and docetaxel predicts of pathological response and disease free survival. Breast Cancer Res Treat. 2008;110:531–9.
3. Horimoto Y, Arakawa A, Harada-Shoji N, et al. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases. Br J Cancer. 2015;112:345–51.
4. Ohtani S, Masuda N, Im Y-H, et al. Adjuvant capecitabine in breast cancer patients with pathologic residual disease after neoadjuvant chemotherapy: first safety analysis of CREATE-X [abstract P3-12-03]. San Antonio Breast Cancer Symposium (SABCS); 2013: San Antonio.
5. Hoffman-La Roche F. A study of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE) [ClinicalTrials.gov identifier: NCT01772472]. US National Institutes of Health, ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01772472 .
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献